Alnylam Pharmaceuticals (ALNY): Assessing the Road to $400
Key Takeaways
- Target in focus: $400 per share, roughly 50% above ALNY's recent trading range near $265 and closely aligned with the analyst consensus of about $394–$412.
- Strongest bullish factor: Rapid uptake of AMVUTTRA in transthyretin amyloidosis cardiomyopathy (ATTR-CM), with the TTR franchise exceeding $1 billion in quarterly revenue.
- Biggest obstacle: The July 2026 reduction in full-year TTR revenue guidance and questions about the sustainability of post-launch demand growth.
- Key levels: The 52-week high of $495.55 and the psychological $400 zone overhead; support near the $197.81 52-week low and the $265 area where shares have stabilized.
- Bottom line: Reaching $400 is plausible over a multi-quarter horizon but depends on renewed execution, not simply a snap-back in sentiment.
Why $400 Stands Out as a Key Level
In my view, $400 carries weight for several reasons. It represents a clear psychological round-number milestone. It also aligns closely with the consensus analyst price target, lending it institutional weight. Finally, ALNY has already traded above this level in the past year, so the zone reflects a recovery target rather than uncharted ground.
ALNY's Current Market Position
Alnylam Pharmaceuticals has transitioned from a research-focused biotech into a commercial entity with six marketed medicines, among them AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, and partnered assets like Leqvio (with Novartis) and Qfitlia (with Sanofi). Revenue rose 65% to roughly $3.7 billion in 2025, and the company achieved GAAP profitability.
Volatility intensified in July 2026 after second-quarter results, which showed 67% revenue growth to $1.29 billion and a return to profit, were overshadowed by a guidance cut. Management reduced its 2026 TTR revenue outlook by about $200 million at the midpoint, pointing to slower normalization of second-line AMVUTTRA demand following an initial surge. Shares dropped roughly 28% in one session, touching the 52-week low of $197.81 before recovering to the mid-$260s. I also checked this using Tickeron’s AI Screener to compare the stock’s recent behavior with peers.
Factors That Could Support Further Gains
AMVUTTRA continues to drive results. Approved for ATTR-CM in May 2025, it remains the only therapy cleared for both cardiomyopathy and polyneuropathy forms of ATTR amyloidosis and has taken a majority of new patient starts among experienced prescribers. The TTR franchise surpassed $1 billion in quarterly revenue, a pace management reached ahead of historical benchmarks set by competitors.
Looking further out, the pipeline includes Nucresiran, a next-generation TTR silencer with potential launch around 2030, and zilebesiran, a blood-pressure candidate partnered with Roche. These assets support the company’s “Alnylam 2030” plan for ongoing revenue growth and margin expansion. A $3.3 billion cash balance provides flexibility to advance these programs.
Potential Headwinds to Monitor
The main risk centers on whether the ATTR-CM launch regains momentum. Competition has increased, with Pfizer’s Vyndamax, BridgeBio’s Attruby, and Ionis Pharmaceuticals’ eplontersen all active in related ATTR markets. If second-line demand remains subdued, additional guidance revisions could weigh on the stock.
Valuation and sentiment also present challenges. Even after the decline, ALNY trades at a premium to many biotech peers, and the post-guidance environment has included target reductions along with greater shareholder scrutiny. A rich multiple implies that sustained gains will require continued earnings and revenue progress rather than stabilization alone.
Analyst Perspectives and Price Targets
Wall Street stays generally constructive, though views have become more varied. Consensus targets sit in the $394–$412 range, pointing to notable upside from current levels. After the guidance cut, some firms lowered targets—Oppenheimer and RBC Capital to around $350, Stifel to roughly $318—while Barclays maintained a higher figure near $450. This spread highlights that the route to $400 remains credible yet less universally expected than before the July adjustment.
Important Technical Levels
From a technical standpoint, $400 acts as both psychological resistance and a prior support area from 2025 trading. A sustained advance would likely need to clear intermediate levels and confirm buying interest above the mid-$260s consolidation zone. The $197.81 low serves as the key downside marker, while the $495.55 high defines the upper end of the past year’s range. From what I see, monitoring these zones closely helps frame risk-reward scenarios.
Using Tickeron AI Daily Buy/Sell Signals for Monitoring
I’ve found Tickeron’s AI Daily Buy/Sell Signals helpful when tracking momentum shifts across a broad set of stocks and ETFs. The platform applies AI analysis to technical behavior and market conditions to generate Buy, Sell, or Hold signals, allowing me to surface opportunities and review existing positions more efficiently than manual review alone. It serves as a practical addition to my regular research process.
Final Assessment
Reaching $400 represents a realistic though not assured outcome for ALNY. The supporting case rests on AMVUTTRA’s clinical and commercial progress, a substantial pipeline, and a solid cash position—all of which could underpin a recovery if the ATTR-CM launch stabilizes. The opposing case rests on the recent guidance reset, rising competition, and a premium valuation that offers limited margin for further shortfalls. Investors will want to watch AMVUTTRA prescription trends, any updates to 2026 guidance, and advancement on nucresiran and zilebesiran, as these elements will shape whether the path back to $400 holds.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALNY in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 01, 2026
ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 33 cases where ALNY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for ALNY crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 68%.
Following a +3.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 224 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 145 of 187 cases where ALNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In 54 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.
The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
ALNY moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.253) is normal, around the industry mean (26.780). P/E Ratio (44.488) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics based on RNA interference
Industry Biotechnology
Advertisement